CD163 detection in immune check-point inhibitors-related acute interstitial nephritis
CD163-M are detected in ICI-AIN and correlate both with severity at diagnosis and better prognosis at 3 months. CD163-M may help us to distinguish AIN from ATN but, it does not allow us to assess ICI imputability. Although detected in urine, usCD163 is clearly not a surrogate biomarker for AIN diagnosis.
Authors
- Ana S. Ramírez (ORCID: https://orcid.org/0000-0002-8721-775X)
- Nathalie Van Acker (ORCID: https://orcid.org/0000-0003-0420-5081)
- Audrey Casemayou
- Thomas Perier
- Magali Colombat
- Thibaut Jamme (ORCID: https://orcid.org/0009-0000-4437-3448)
- James R. Pellegrini (ORCID: https://orcid.org/0000-0002-6317-3000)
- Clément Kounde
- Yves Renaudineau (ORCID: https://orcid.org/0000-0001-5098-5002)
- Julie Bellière (ORCID: https://orcid.org/0000-0002-4229-8584)
- Pierre Guy (ORCID: https://orcid.org/0009-0005-1727-8986)
- David Ribes
- Antoine Huart (ORCID: https://orcid.org/0009-0002-3898-8731)
Institutions
- Université Toulouse III - Paul Sabatier (FR)
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Laboratoire de Biologie Structurale de la Cellule (FR)
- Institut des Maladies Métaboliques et Cardiovasculaires (FR)
- French Clinical Research Infrastructure Network (FR)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1093/ckj/sfaf009
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18